Insider Transactions in Q3 2025 at Ionis Pharmaceuticals Inc (IONS)
Insider Transaction List (Q3 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 06
2025
|
B Lynne Parshall Director |
SELL
Open market or private sale
|
Direct |
5,000
-2.75%
|
$210,000
$42.25 P/Share
|
|
Aug 05
2025
|
Richard S Geary EVP, Chief Development Officer |
SELL
Open market or private sale
|
Direct |
10,000
-10.05%
|
$420,000
$42.86 P/Share
|
|
Aug 04
2025
|
Eugene Schneider EVP, Chf Clinical Develop Ofcr |
SELL
Open market or private sale
|
Direct |
9,549
-15.64%
|
$401,058
$42.8 P/Share
|
|
Jul 30
2025
|
Brett P Monia Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,432
-1.33%
|
$109,440
$45.0 P/Share
|
|
Jul 30
2025
|
Brett P Monia Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,432
+1.32%
|
$77,824
$32.6 P/Share
|
|
Jul 15
2025
|
Joseph Loscalzo Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,079
+10.09%
|
-
|
|
Jul 15
2025
|
Spencer R Berthelsen Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,079
+2.55%
|
-
|
|
Jul 15
2025
|
Allene M. Diaz Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,079
+17.09%
|
-
|
|
Jul 15
2025
|
Michael R Hayden Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,079
+6.99%
|
-
|
|
Jul 15
2025
|
Joan E Herman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,079
+8.13%
|
-
|
|
Jul 15
2025
|
B Lynne Parshall Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,079
+4.27%
|
-
|
|
Jul 15
2025
|
Joseph H Wender Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
4,079
+2.89%
|
-
|
|
Jul 15
2025
|
Michael J. Yang Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,079
+40.43%
|
-
|
|
Jul 11
2025
|
Brett P Monia Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,160
-0.64%
|
$47,560
$41.74 P/Share
|